Key Points
- Director Lewis Titterton, Jr. purchased 8,000 Anixa Biosciences shares at an average price of $2.98, investing $23,840 and increasing his stake by 0.76% to 1,054,003 shares.
- ANIX shares opened at $2.93, with a market capitalization of approximately $101.85 million and a 52-week range of $2.32 to $5.46. The company reported a quarterly loss of $0.08 per share, in line with analyst expectations.
- Analyst sentiment is mixed, with three Buy ratings, one Hold, and one Sell; the consensus rating is Hold with an $8.00 price target. Institutional investors and hedge funds own 29.13% of the stock.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) Director Lewis Titterton, Jr. purchased 8,000 shares of the firm's stock in a transaction dated Friday, October 23rd. The stock was acquired at an average cost of $2.98 per share, with a total value of $23,840.00. Following the purchase, the director owned 1,054,003 shares of the company's stock, valued at approximately $3,140,928.94. This represents a 0.76% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Anixa Biosciences Stock Performance
Shares of ANIX opened at $2.93 on Tuesday. The firm has a market capitalization of $101.85 million, a price-to-earnings ratio of -9.16 and a beta of 0.47. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46. The stock's fifty day moving average is $3.00 and its 200-day moving average is $2.97.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). Analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.
Hedge Funds Weigh In On Anixa Biosciences
Several hedge funds have recently modified their holdings of ANIX. Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences in the 2nd quarter worth $29,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Anixa Biosciences in the second quarter valued at $29,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at $30,000. Simplicity Wealth LLC bought a new position in Anixa Biosciences during the second quarter valued at about $34,000. Finally, NewEdge Wealth LLC bought a new position in Anixa Biosciences during the second quarter valued at about $35,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Citigroup reissued a "buy" rating on shares of Anixa Biosciences in a research note on Tuesday, October 6th. HC Wainwright dropped their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, September 22nd. Zacks Research lowered shares of Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Weiss Ratings raised shares of Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 17th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.00.
Check Out Our Latest Stock Analysis on ANIX
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company's programs are designed to use the immune system to identify and attack disease-associated targets.
Anixa's oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
